By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Crucell N.V. 

Archimedesweg 4
P.O. Box 2048
CA Leiden    2301  The Netherlands
Phone: 31-0-71-524-8701 Fax: 31-0-71-524-8702




Company News
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/20/2014 3:28:01 AM
Johnson & Johnson (JNJ) Jumps Into The Ebola Race With Collaboration Of Crucell (JNJ) And Bavarian Nordic (BAVA.CO); Human Trials To Start In Early 2015 9/4/2014 6:06:51 AM
Mucosis B.V. Signs Research and License Option Agreement With Crucell N.V. (CRXL) 10/8/2012 10:44:12 AM
CLC bio Delivers Specialized Antibody Engineering and Selection Software for Crucell N.V. (CRXL) 6/8/2012 9:33:51 AM
ARTES Biotechnology Announces a Strategic Collaboration Deal for Vaccine Development 4/24/2012 9:54:26 AM
Judgment Issued in Crucell N.V. (CRXL) Buy-Out Proceedings 2/28/2012 9:02:25 AM
Crucell N.V. (CRXL) Release: Promising Results of Novel Combination Vaccine 1/5/2012 11:09:37 AM
Crucell N.V. (CRXL) Discovers Important New Antibody Against Influenza A 7/8/2011 9:28:26 AM
Isconova Enters into Adjuvant License Agreement with Crucell N.V. (CRXL) 6/9/2011 9:25:39 AM
Crucell N.V. (CRXL), GlaxoSmithKline (GSK) And PATH MVI Partner to Develop Second-Generation Vaccine Against Malaria 6/7/2011 7:54:15 AM